CRCL
MCID: CRT084
MIFTS: 22

Creatinine Clearance Quantitative Trait Locus (CRCL)

Data Licensing
For inquiries, contact:

Aliases & Classifications for Creatinine Clearance Quantitative Trait Locus

MalaCards integrated aliases for Creatinine Clearance Quantitative Trait Locus:

Name: Creatinine Clearance Quantitative Trait Locus 57
Creatinine Clearance Qtl 57 12
Crcl 57

External Ids:

OMIM® 57 607135

Summaries for Creatinine Clearance Quantitative Trait Locus

MalaCards based summary: Creatinine Clearance Quantitative Trait Locus, also known as creatinine clearance qtl, is related to rapidly involuting congenital hemangioma and osteoporosis. An important gene associated with Creatinine Clearance Quantitative Trait Locus is CRCL (Creatinine Clearance QTL). The drugs Thrombin and Dabigatran have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver.

More information from OMIM: 607135

Related Diseases for Creatinine Clearance Quantitative Trait Locus

Diseases related to Creatinine Clearance Quantitative Trait Locus via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 11)
# Related Disease Score Top Affiliating Genes
1 rapidly involuting congenital hemangioma 10.2
2 osteoporosis 9.9
3 ovarian cancer 9.9
4 small cell cancer of the lung 9.9
5 bone mineral density quantitative trait locus 8 9.9
6 bone mineral density quantitative trait locus 15 9.9
7 protein-losing enteropathy 9.9
8 chagas disease 9.9
9 adenocarcinoma 9.9
10 mouth disease 9.9
11 pathologic nystagmus 9.9

Graphical network of the top 20 diseases related to Creatinine Clearance Quantitative Trait Locus:



Diseases related to Creatinine Clearance Quantitative Trait Locus

Symptoms & Phenotypes for Creatinine Clearance Quantitative Trait Locus

Clinical features from OMIM®:

607135 (Updated 08-Dec-2022)

Drugs & Therapeutics for Creatinine Clearance Quantitative Trait Locus

Drugs for Creatinine Clearance Quantitative Trait Locus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Dabigatran Approved, Investigational Phase 4 211914-51-1 216210
3 HIV Protease Inhibitors Phase 4
4 Anticoagulants Phase 4
5 Serine Proteinase Inhibitors Phase 4
6 Antithrombins Phase 4
7 Antithrombin III Phase 4
8
protease inhibitors Phase 4
9
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
10 Vaccines Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 An Open Label, Non-comparative, Pharmacokinetic and Pharmacodynamic Study to Evaluate the Effect of Dabigatran Etexilate on Coagulation Parameters Including a Calibrated Thrombin Time Test in Patients With Moderate Renal Impairment (Creatinine Clearance 30-50 ml/Min) Undergoing Primary Unilateral Elective Total Knee or Hip Replacement Surgery Completed NCT01184989 Phase 4 Dabigatran etexilate
2 Phase IIA Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma Completed NCT02409524 Phase 2
3 Natural Course for Renal Function After Heart Transplantation Unknown status NCT02541981
4 How to Dose a Patient According to Renal Function? Glomerular Filtration Rate (GFR) or Creatinine Clearance (ClCr) Unknown status NCT02206373
5 Post-authorisation Observational Study for the Assessment of Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance <50 mL/Min/1.73 m2 (CrCl <50 mL/Min/1.73 m2) Completed NCT02849444

Search NIH Clinical Center for Creatinine Clearance Quantitative Trait Locus

Genetic Tests for Creatinine Clearance Quantitative Trait Locus

Anatomical Context for Creatinine Clearance Quantitative Trait Locus

Organs/tissues related to Creatinine Clearance Quantitative Trait Locus:

MalaCards : Kidney, Heart, Liver, Lung, Bone, Bone Marrow, Brain

Publications for Creatinine Clearance Quantitative Trait Locus

Articles related to Creatinine Clearance Quantitative Trait Locus:

(show top 50) (show all 1793)
# Title Authors PMID Year
1
A genome scan for renal function among hypertensives: the HyperGEN study. 57
11115379 2001
2
Toxicokinetics and toxicodynamics of chromium in the soil invertebrate Enchytraeus crypticus (Oligochaeta). 62
36328254 2023
3
Estimation of Kidney Function in Patients With Multiple Myeloma: Implications for Lenalidomide Dosing. 62
35511200 2023
4
Renal function in abdominal neuroblastoma patients undergoing proton radiotherapy. 62
36129239 2023
5
Drug dose adjustment in patients with renal impairment attending a specialized referral hospital, Northwest Ethiopia. 62
36177456 2022
6
Evaluation of standard versus reduced dose apixaban for the treatment of venous thromboembolism in patients with severe renal disease (ESRD-VTE). 62
36306678 2022
7
Physical Vapor Transport Growth of Antiferromagnetic CrCl3 Flakes Down to Monolayer Thickness. 62
36453569 2022
8
Efficacy and Safety of Add-on Mirogabalin to NSAIDs in Lumbar Spinal Stenosis with Peripheral Neuropathic Pain: A Randomized, Open-Label Study. 62
35857196 2022
9
A systematic review of the efficacy and safety of anticoagulants in advanced chronic kidney disease. 62
36006608 2022
10
Prevalence and predictors of inappropriate dosing of direct oral anticoagulants. 62
36448650 2022
11
Individualized optimization of colistin loading doses. 62
36323974 2022
12
Haematological and renal toxicity of radiation therapy in neuroblastoma paediatric patients. 62
36342652 2022
13
Real-world data for the renal safety of abemaciclib combined with bisphosphonate in HR+/HER2- advanced breast cancer. 62
36351632 2022
14
Empirical Antibiotic Therapy for Gram-Negative Bacilli Ventilator-Associated Pneumonia: Observational Study and Pharmacodynamic Assessment. 62
36421308 2022
15
Performance of different body weights in the Cockcroft-Gault equation in critically ill patients with and without augmented renal clearance: A multicenter cohort. 62
36373197 2022
16
Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones. 62
35943868 2022
17
Gate-Tunable Proximity Effects in Graphene on Layered Magnetic Insulators. 62
36279401 2022
18
Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis. 62
36316100 2022
19
Recent Progress in Research on Ferromagnetic Rhenium Disulfide. 62
36234579 2022
20
Chromium-Based Complexes Bearing N-Substituted Diphosphinoamine Ligands for Ethylene Oligomerization. 62
36249395 2022
21
Critical appraisal of evidence for anti-Xa monitoring and dosing of low-molecular-weight heparin in renal insufficiency. 62
36189469 2022
22
Benefit of medication reviews by renal pharmacists in the setting of a computerized physician order entry system with clinical decision support. 62
35868964 2022
23
Exploring the past to inform the future to optimize the pharmacokinetics of vancomycin in children with severe burn injuries. 62
36194537 2022
24
Impact of baseline renal function on the efficacy and safety of different Anticoagulants in Atrial Fibrillation Patients - A cohort study. 62
36229879 2022
25
Population Pharmacokinetic Modeling for Ceftazidime-Avibactam Renal Dose Adjustments in Pediatric Patients 3 months and Older. 62
36239478 2022
26
The Predictive Ability of the Renal Resistive Index and Its Relationship to Duplex Ultrasound Waveform Propagation in the Aorta and Renal Arteries. 62
35470047 2022
27
Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review. 62
36381830 2022
28
Influence of tibial plateau levelling osteotomy on the tensile forces sustained by ligaments in cranial cruciate ligament-intact canine stifles: An ex vivo pilot study. 62
35947706 2022
29
Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study. 62
35395094 2022
30
Association Between Contrast Volume-to-Creatinine Clearance Ratio and the Risk of Perioperative Myocardial Infarction After Elective Percutaneous Coronary Intervention. 62
36104241 2022
31
Tolerability and treatment outcome of pembrolizumab in patients with advanced urothelial carcinoma and severe renal dysfunction. 62
35551861 2022
32
Influence of Renal Function on Phosphoramide Mustard Exposure: A Nonlinear Mixed-Effects Analysis. 62
36063026 2022
33
Trends in direct oral anticoagulant (DOAC) prescribing in English primary care (2014-2019). 62
36371664 2022
34
Augmented renal clearance in the ICU: estimation, incidence, risk factors and consequences-a retrospective observational study. 62
36156744 2022
35
Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings. 62
35697255 2022
36
Impact of Elevated LDH on Cystatin C-Based Glomerular Filtration Rate Estimates in Patients with Cancer. 62
36143104 2022
37
Microleakage assessment of CAD-CAM Cobalt-Chrome and Zirconia abutments on a conical connection dental implant: A comparative in vitro study. 62
35818785 2022
38
Band Gap Opening in Bilayer Graphene-CrCl3/CrBr3/CrI3 van der Waals Interfaces. 62
35930625 2022
39
Glomerular filtration rate in critically ill neonates and children: creatinine-based estimations versus iohexol-based measurements. 62
35916956 2022
40
Amikacin pharmacokinetics in elderly patients with severe infections. 62
35618200 2022
41
TEMPO coordination and reactivity in group 6; pseudo-pentagonal planar (η2-TEMPO)2CrX (X = Cl, TEMPO). 62
35975596 2022
42
Population Pharmacokinetics and Dose Optimization Based on Renal Function of Rivaroxaban in Thai Patients with Non-Valvular Atrial Fibrillation. 62
36015370 2022
43
Incidence and determinats of augmented renal clearance in traumatic brain injury: A prospective observational study. 62
35605338 2022
44
Unprecedented Ferroelectricity and Ferromagnetism in a Cr2+ -Based Two-Dimensional Hybrid Perovskite. 62
35604204 2022
45
<Editors' Choice> Clinical impact of standardized creatinine on dose adjustment of capecitabine. 62
36237888 2022
46
Comparison between Creatinine Clearance and eGFRcyst-crea: a real-life experience. 62
36073332 2022
47
Augmented Renal Clearance in Patients with Acute Ischemic Stroke: A Prospective Observational Study. 62
35918629 2022
48
Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial. 62
35858874 2022
49
Synthesis of micro- and nanosheets of CrCl3-RuCl3 solid solution by chemical vapour transport. 62
35822883 2022
50
Contrast Media Volume to Creatinine Clearance Ratio in Predicting Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. 62
35815550 2022

Variations for Creatinine Clearance Quantitative Trait Locus

Expression for Creatinine Clearance Quantitative Trait Locus

Search GEO for disease gene expression data for Creatinine Clearance Quantitative Trait Locus.

Pathways for Creatinine Clearance Quantitative Trait Locus

GO Terms for Creatinine Clearance Quantitative Trait Locus

Sources for Creatinine Clearance Quantitative Trait Locus

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....